The Impact of Patient, Disease, and Social Determinants of Health on Receipt of Nonoperative Management for Patients With Rectal Adenocarcinoma.

IF 1.8 4区 医学 Q4 ONCOLOGY
Keaton A Rummel, Christopher L Hallemeier, Zhaohui Jin, Kenneth W Merrell, Hao Xie, Kellie L Mathis, Nicholas P McKenna, Mark R Waddle, Michael G Haddock, Cameron M Callaghan, Krishan R Jethwa
{"title":"The Impact of Patient, Disease, and Social Determinants of Health on Receipt of Nonoperative Management for Patients With Rectal Adenocarcinoma.","authors":"Keaton A Rummel, Christopher L Hallemeier, Zhaohui Jin, Kenneth W Merrell, Hao Xie, Kellie L Mathis, Nicholas P McKenna, Mark R Waddle, Michael G Haddock, Cameron M Callaghan, Krishan R Jethwa","doi":"10.1097/COC.0000000000001243","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>For locally advanced rectal adenocarcinoma (R-ACA), a nonoperative management (NOM) approach has emerged as a guideline-supported treatment option. However, the variables associated with NOM receipt are unknown.</p><p><strong>Methods: </strong>Utilizing the National Cancer Database, we performed a retrospective cohort study of adults with stage 1 to 3 R-ACA managed with curative intent from 2004 to 2018. The primary outcome was the proportion of patients receiving NOM versus surgery. The secondary outcome was survival among NOM patients.</p><p><strong>Results: </strong>A total of 128,297 patients were included. In all, 115,888 (90.3%) received surgery and 12,409 (9.7%) received NOM. Receipt of NOM was associated with age above 70, Charlson-Deyo score of 0, race (Black, Asian or Pacific Islander, or other vs. White), insurance status, geographical region, treatment in a community facility, year of diagnosis (2012-2018 vs. 2004-2011), tumor grade 1 versus ≥ 2, clinical T-stage ≥ 2, and clinical N1 or N2 versus N0. In the NOM cohort, poorer overall survival was associated with age 70 and above, male sex, Charlson-Deyo score ≥ 1, insurance status, geographical region, rural urban density versus metro/urban, treatment in a community facility, year of diagnosis (2004-2011 vs. 2012-2018), clinical T4 versus T1, clinical N1 or N2 versus N0, grade 3 versus 1, treatment with a radiotherapy dose <45 Gy versus 45 to 54 Gy, and omission of chemotherapy.</p><p><strong>Conclusions: </strong>Several demographic factors and social determinants of health were associated with receipt of NOM and overall survival. With the increasing utilization of NOM, it will be important to understand the drivers of treatment decisions and influences on access to the desired treatment approach.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: For locally advanced rectal adenocarcinoma (R-ACA), a nonoperative management (NOM) approach has emerged as a guideline-supported treatment option. However, the variables associated with NOM receipt are unknown.

Methods: Utilizing the National Cancer Database, we performed a retrospective cohort study of adults with stage 1 to 3 R-ACA managed with curative intent from 2004 to 2018. The primary outcome was the proportion of patients receiving NOM versus surgery. The secondary outcome was survival among NOM patients.

Results: A total of 128,297 patients were included. In all, 115,888 (90.3%) received surgery and 12,409 (9.7%) received NOM. Receipt of NOM was associated with age above 70, Charlson-Deyo score of 0, race (Black, Asian or Pacific Islander, or other vs. White), insurance status, geographical region, treatment in a community facility, year of diagnosis (2012-2018 vs. 2004-2011), tumor grade 1 versus ≥ 2, clinical T-stage ≥ 2, and clinical N1 or N2 versus N0. In the NOM cohort, poorer overall survival was associated with age 70 and above, male sex, Charlson-Deyo score ≥ 1, insurance status, geographical region, rural urban density versus metro/urban, treatment in a community facility, year of diagnosis (2004-2011 vs. 2012-2018), clinical T4 versus T1, clinical N1 or N2 versus N0, grade 3 versus 1, treatment with a radiotherapy dose <45 Gy versus 45 to 54 Gy, and omission of chemotherapy.

Conclusions: Several demographic factors and social determinants of health were associated with receipt of NOM and overall survival. With the increasing utilization of NOM, it will be important to understand the drivers of treatment decisions and influences on access to the desired treatment approach.

患者、疾病和健康的社会决定因素对直肠腺癌患者接受非手术治疗的影响
目的:对于局部晚期直肠腺癌(R-ACA),非手术治疗(NOM)方法已成为一种指南支持的治疗选择。然而,与NOM接收相关的变量是未知的。方法:利用国家癌症数据库,我们对2004年至2018年以治疗为目的的1至3期R-ACA成人进行了回顾性队列研究。主要结局是接受NOM和手术的患者比例。次要终点是NOM患者的生存。结果:共纳入128,297例患者。总共有115,888人(90.3%)接受了手术,12,409人(9.7%)接受了NOM。接受NOM与年龄大于70岁、Charlson-Deyo评分为0、种族(黑人、亚洲人或太平洋岛民,或其他与白人)、保险状况、地理区域、社区设施治疗、诊断年份(2012-2018年与2004-2011年)、肿瘤分级1与≥2、临床t期≥2、临床N1或N2与N0相关。在NOM队列中,较差的总生存率与年龄70岁及以上、男性、Charlson-Deyo评分≥1、保险状况、地理区域、农村城市密度与城市/城市密度、社区设施治疗、诊断年份(2004-2011年vs 2012-2018年)、临床T4与T1、临床N1或N2与N0、3级与1级、放疗剂量相关。一些人口因素和健康的社会决定因素与接受NOM和总生存率有关。随着NOM的使用越来越多,了解治疗决策的驱动因素以及对获得所需治疗方法的影响将变得非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
130
审稿时长
4-8 weeks
期刊介绍: ​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信